Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
Yu, Evan Y.
Wu, Haiyan
Schloss, Charles
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS5089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5089
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [2] Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Cohorts A-C of the Phase 1b/2 KEYNOTE-365 Study
    Joshua, Anthony M.
    Gurney, Howard
    Retz, Margitta
    Tafreshi, Ali
    Fong, Peter
    Shore, Neal
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Berry, William R.
    Kolinsky, Michael Paul
    Sridhar, Srikala S.
    Conter, Henry Joacob
    Todenhofer, Tilman
    Appleman, Leonard J.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    de Bono, Johann S.
    Yu, Evan Y.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 46 - 47
  • [3] KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer
    Appleman, Leonard
    Piulats, Josep
    Mar, Nataliya
    Arranz, Jose
    Joshua, Anthony
    Mayer, Tina
    Shore, Neal
    Wu, Haiyan
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [5] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
    Kramer, Gero
    Shore, Neal
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
  • [6] PEMBROLIZUMAB plus VIBOSTOLIMAB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS G/H
    Shore, Neal
    De Bono, Johann
    Kramer, Gero
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A455 - A455
  • [7] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arija, Jose Angel Arranz
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Feyerabend, Susan
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Kramer, Gero
    Shore, Neal D.
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab plus vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Shore, Neal D.
    De Bono, Johann S.
    Kramer, Gero
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
    Yu, Evan Y.
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Conter, Henry J.
    Laguerre, Brigitte
    Fong, Peter C. C.
    Ferrario, Cristiano
    Todenhofer, Tilman
    Gravis, Gwenaelle
    Piulats, Josep M.
    Emmenegger, Urban
    Shore, Neal D.
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian H.
    Schloss, Charles
    Appleman, Leonard J.
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 509 - 518
12345